Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34871550

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Jan
First author
Usmani SZ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Mar;23(3):e97. doi: 10.1016/S1470-2045(22)00075-4.
    note
    Source null
    related pmid
    35240098
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Mar;23(3):e98. doi: 10.1016/S1470-2045(22)00077-8.
    note
    Source null
    related pmid
    35240099
    relationship
    Comment in

Authors and identifiers

  1. name
    Usmani SZ
    type
    Author
  2. name
    Quach H
    type
    Author
  3. name
    Mateos MV
    type
    Author
  4. name
    Landgren O
    type
    Author
  5. name
    Leleu X
    type
    Author
  6. name
    Siegel D
    type
    Author
  7. name
    Weisel K
    type
    Author
  8. name
    Gavriatopoulou M
    type
    Author
  9. name
    Oriol A
    type
    Author
  10. name
    Rabin N
    type
    Author
  11. name
    Nooka A
    type
    Author
  12. name
    Qi M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Usmani SZ
    type
    Author
  2. name
    Quach H
    type
    Author
  3. name
    Mateos MV
    type
    Author
  4. name
    Landgren O
    type
    Author
  5. name
    Leleu X
    type
    Author
  6. name
    Siegel D
    type
    Author
  7. name
    Weisel K
    type
    Author
  8. name
    Gavriatopoulou M
    type
    Author
  9. name
    Oriol A
    type
    Author
  10. name
    Rabin N
    type
    Author
  11. name
    Nooka A
    type
    Author
  12. name
    Qi M
    type
    Author
bibliography ids
  1. nci-bib-8df479c17d8aea5b6190578f
book metadata
content sha256
b20e663fcf83c18641bd77687edcd63d6aaaa7477d3bf29808d6614c8d3107f7
document type
citation
dois
  1. 10.1016/S1470-2045(21)00579-9
electronic publication date
display
2021 Dec 3
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34871550
immutable id
pubmed:34871550@b20e663fcf83c18641bd77687edcd63d6aaaa7477d3bf29808d6614c8d3107f7
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
65-76
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Mar;23(3):e97. doi: 10.1016/S1470-2045(22)00075-4.
    note
    Source null
    related pmid
    35240098
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Mar;23(3):e98. doi: 10.1016/S1470-2045(22)00077-8.
    note
    Source null
    related pmid
    35240099
    relationship
    Comment in
outcomes validated
false
pmid
34871550
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
c5b775374dc4e38f9c390b23e4af01e44723d4a06a765278ce2fd3e2f064bdbb
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Jan
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34871550/
title
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

Preserved source evidence · Not medical advice